This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WAISMANN METHOD® Medical Director Expresses Concern About Shift In Opioid Drug Use

BEVERLY HILLS, Calif., Jan. 2, 2013 /PRNewswire/ -- An "abuse-proof" formulation of OxyContin may have helped reduce the number of patients abusing the drug, but Dr. Michael Lowenstein, medical director for WAISMANN METHOD® opiate detoxification and treatment, is voicing alarm at recent data showing it may have consequentially resulted in a sharp increase in heroin and other opioid drug use.

"After the new abuse-resistant OxyContin was released, I expressed concerns that it could encourage patients to migrate to other, sometimes more dangerous opioid drugs," said Dr. Lowenstein. "Two years later this fear has become a reality, as the New England Journal of Medicine reported a huge increase in high-potency prescription opioids while heroin use nearly doubled.  Patient education is more important now than ever before, so we can work to actually help alleviate people of their addictions to opioids rather than replace one narcotic for another."

The NEJM study scrutinized data from 2,566 patients with opioid dependence, and found that abuse of OxyContin as the primary drug decreased from 35.6 percent to 12.8 percent from July 1, 2009 to March 31, 2012. During the same time period, respondent figures showed a rise in use of opioids, like hydrocodone and oxycodone, and powerful opioids, like fentanyl and hydromorphone, which rose from 20.1 percent to 32.3 percent. Data collected from WAISMANN METHOD® patients between January and December 2011 also showed similar trends. During this time, there was an 80 percent decrease in the number of patients treated for OxyContin dependency compared to those in 2010. At the same time, oxycodone patients treated at the facility went up by 35 percent.

According to the NEJM study, heroin was the most common opioid being used among the 66 percent who indicated they had switched after the abuse-resistant OxyContin was released.  Qualitative responses from the study indicated many patients who switched to heroin did so because it was easier to obtain and more economical than prescription drugs. One participant said, "Most people that I know don't use OxyContin to get high anymore. They have moved on to heroin [because] it is easier to use, much cheaper and easily available."

"We want patients struggling with opioid addiction to know that there are true solutions, and that they don't have to continue to put their lives in danger by using prescription painkillers or switching to illicit street drugs like heroin," continued Dr. Lowenstein. "Abuse-resistant drugs are not the answer, and we in the medical community have a responsibility to do more for our patients so they can eventually live drug-free lives."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs